Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Equal-Weight rating on Beam Therapeutics (NASDAQ:BEAM) but lowers the price target from $33 to $31.
August 07, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Gena Wang maintains an Equal-Weight rating on Beam Therapeutics but lowers the price target from $33 to $31.
The lowered price target from $33 to $31 by Barclays suggests a slightly less optimistic outlook for Beam Therapeutics, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100